Stiolto Respimat (Tiotropium Br/Olodaterol HCl) Patent Expiration, LOE Window & CMS Spending

Stiolto Respimat (Tiotropium Br/Olodaterol HCl) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2027-01-19 (last listed 2028-09-13), 0 AB generics, $517.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN206756 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2027-01-19
Last Listed Patent or Exclusivity Date2028-09-13
Orange Book Patents (*PED Extensions)3 patents (2 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$517.5M
2024 Medicare Part D Spend$448.6M
2024 Medicaid Spend$68.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.